Ultra‐Rapid Lispro results in accelerated insulin lispro absorption and faster early insulin action in comparison with Humalog(®) in Japanese patients with type 1 diabetes

AIMS/INTRODUCTION: Ultra‐rapid lispro (URLi) is a novel ultra‐rapid mealtime insulin. This study compared the pharmacokinetic and glucodynamic profiles, safety, and tolerability of URLi and lispro (Humalog(®)) in Japanese patients with type 1 diabetes mellitus. MATERIALS AND METHODS: This was a phas...

Descripción completa

Detalles Bibliográficos
Autores principales: Shiramoto, Masanari, Nasu, Risa, Oura, Tomonori, Imori, Makoto, Ohwaki, Kenji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7232298/
https://www.ncbi.nlm.nih.gov/pubmed/31816193
http://dx.doi.org/10.1111/jdi.13195

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7232298/
https://www.ncbi.nlm.nih.gov/pubmed/31816193
http://dx.doi.org/10.1111/jdi.13195

Ejemplares similares